TCT 2022 | FAME-3 Trial: post PCI FFR And IVUS in Patients with Three-Vessel Disease

We are well aware of the benefits of Fractional Flow Reserve (FFR) to assess coronary artery stenosis. FFR after PCI (post-PCI FFR) has been shown to have prognostic value; however, few studies have included patients with complex three-vessel disease. The impact of intravascular ultrasound (IVUS) or optical computer tomography (OCT) in this field has been even more overlooked.  

TCT 2022

The aim of this multicenter randomized study was to assess the prognostic value of post PCI FFR and intravascular imaging in patients undergoing PCI for three vessel disease in the FAME 3. 

Primary end point was target vessel failure (TVF), a combination of cardiovascular death, treated vessel MI (TVMI) and target vessel revascularization (TVR) at 1 year. 

Of 1500 patients included in the FAME 3 trial, 757 were randomized to FFR guided PCI. Of these, 61% were measured with FFR after PCI, and 15% had three-vessel disease. The artery most frequently assessed was the anterior descending, followed by the right coronary. Mean FFR value was 0.89. 9.1% had post PCI FFR 0.8 or lower. Post PCI FFR in the anterior descending artery was 0.87, while mean post PCI FFR in any other artery was 0.92.

Post PCI FFR value was a significant predictor of TVF at 1 year (HR=0.67 [95% CI: 0.48-0.93]. There was a significant and progressive reduction of TVF according to post PCI FFR values. 

Read also: TCT 2022 | BYPASS CTCA.

As regard IVUS imaging, there were no differences in cardiovascular death rate, AMI or the need for repeat revascularization vs. patients with no IVUS imaging. 

Conclusion

Post PCI FFR was an independent predictor of TVF in patients with three-vessel disease. The use of IVUS had no effect on the assessed outcomes. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Prognostic Value of Measuring Fractional Flow Reserve after Percutaneous Coronary Intervention in Patients with Complex Coronary Artery Disease: Insights from the FAME 3 Trial.

Reference: Zsolt Piroth, MD, PhD et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...